OABI
OmniAbDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The bull case is that OmniAb’s 107 active partners, 407 active programs and growing set of later-stage partnered assets can gradually convert a low-revenue platform story into a milestone-and-royalty story, while OmniUltra and xPloration widen platform relevance and help sustain partner additions [#8-K-2026-03-04].
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
2026 guidance still implies meaningful cash burn and a lower year-end cash balance.
Momentum
87
Value
41
Sentiment
17
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1.40 · Bull $2.40 · Bear $0.70
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $7.36
Why
Momentum87 · Δ7d -
Value41 · Δ7d +0.0
Sentiment17 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
87
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
17
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 86.8 / Value 41.1 / Sentiment 16.7
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$301.54M
Beta
0.15
Shares Out
144.97M
P/E (TTM) · Derived
-3.6
P/S (TTM)
12.63
P/FCF (TTM) · Derived
-9.42
Rev YoY
+247.3%
EPS YoY
-65.1%
Gross Margin
+15.2%
Op Margin
-327.5%
Net Debt
-$33.69M
Current Ratio
4.80
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology